{"id":"tp-40655","type":"article-newspaper","title":"Frontier Medicines Reports 56% Response Rate in Phase 1 Lung Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40655","datePublished":"2026-10-25T19:21:14.000Z","dateModified":"2026-10-25T19:21:14.000Z","language":"en","abstract":"The confirmed responses came in 10 of 18 evaluable patients with metastatic non-small cell lung cancer treated after chemotherapy and immunotherapy.","section":"Business","references":[]}